Zimmer BiometZBHEarnings & Financial Report
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Revenue
$2.0B
Gross Profit
$1.4B
Operating Profit
$389.0M
Net Profit
$239.5M
Gross Margin
71.0%
Operating Margin
19.2%
Net Margin
11.8%
YoY Growth
4.3%
EPS
$1.18
Zimmer Biomet Q4 FY2024 Financial Summary
Zimmer Biomet reported revenue of $2.0B (up 4.3% YoY) for Q4 FY2024, with a net profit of $239.5M (down 42.9% YoY) (11.8% margin). Cost of goods sold was $586.7M, operating expenses totaled $1.0B.
Key Financial Metrics
| Total Revenue | $2.0B |
|---|---|
| Net Profit | $239.5M |
| Gross Margin | 71.0% |
| Operating Margin | 19.2% |
| Report Period | Q4 FY2024 |
Zimmer Biomet Annual Revenue by Year
Zimmer Biomet annual revenue history includes year-by-year totals (for example, 2025 revenue was $8.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $8.2B |
| 2024 | $7.7B |
| 2023 | $7.4B |
| 2022 | $6.9B |
Zimmer Biomet Quarterly Revenue & Net Profit History
Zimmer Biomet results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.1B | +9.3% | $238.3M | 11.4% |
| Q4 FY2025 | $2.2B | +10.9% | $139.4M | 6.2% |
| Q3 FY2025 | $2.0B | +9.7% | $230.9M | 11.5% |
| Q2 FY2025 | $2.1B | +7.0% | $152.8M | 7.4% |
| Q1 FY2025 | $1.9B | +1.1% | $182.0M | 9.5% |
| Q4 FY2024 | $2.0B | +4.3% | $239.5M | 11.8% |
| Q3 FY2024 | $1.8B | +4.0% | $249.1M | 13.7% |
| Q2 FY2024 | $1.9B | +3.9% | $242.8M | 12.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $1.82B | $2.02B | $1.91B | $2.08B | $2.00B | $2.24B | $2.09B |
| YoY Growth | 3.9% | 4.0% | 4.3% | 1.1% | 7.0% | 9.7% | 10.9% | 9.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.52B | $21.72B | $21.37B | $22.18B | $22.87B | $23.49B | $23.09B | $22.72B |
| Liabilities | $8.77B | $9.34B | $8.89B | $9.78B | $10.33B | $10.72B | $10.39B | $10.04B |
| Equity | $12.74B | $12.37B | $12.47B | $12.40B | $12.53B | $12.76B | $12.70B | $12.68B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $369.4M | $395.7M | $506.3M | $382.8M | $378.2M | $418.7M | $517.4M | $359.4M |